MAP2K7 and melanoma: Already today, patients with dermal melanoma from AJCC 2017 stage IIIA-D are offered an anti-PD1 therapy, or from stage III A–D with a BRAF V600E or V600K mutation are offered a BRAF and MEK inhibitor, as this prolongs the recurrence-free survival, according to the melanoma guideline [97,98,99].